Does the media prefer KYMR or KOD?

In the previous week, Kymera Therapeutics had 6 more articles in the media than Kodiak Sciences. MarketBeat recorded 10 mentions for Kymera Therapeutics and 4 mentions for Kodiak Sciences. Kodiak Sciences' average media sentiment score of 0.97 beat Kymera Therapeutics' score of 0.50 indicating that Kodiak Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kymera Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Kodiak Sciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is KOD or PRAX more profitable?

Praxis Precision Medicines' return on equity of -43.02% beat Kodiak Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Kodiak Sciences N/A -253.85% -81.48% Praxis Precision Medicines N/A -43.02% -40.22%

Does the media prefer KOD or PRAX?

In the previous week, Praxis Precision Medicines had 2 more articles in the media than Kodiak Sciences. MarketBeat recorded 6 mentions for Praxis Precision Medicines and 4 mentions for Kodiak Sciences. Kodiak Sciences' average media sentiment score of 0.97 beat Praxis Precision Medicines' score of 0.75 indicating that Kodiak Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kodiak Sciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Praxis Precision Medicines 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor KOD or PTGX?

In the previous week, Protagonist Therapeutics had 6 more articles in the media than Kodiak Sciences. MarketBeat recorded 10 mentions for Protagonist Therapeutics and 4 mentions for Kodiak Sciences. Kodiak Sciences' average media sentiment score of 0.97 beat Protagonist Therapeutics' score of 0.67 indicating that Kodiak Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kodiak Sciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Protagonist Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, PCVX or KOD?

Kodiak Sciences is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vaxcyte N/A N/A -$766.63M -$6.88 N/A Kodiak Sciences N/A N/A -$229.97M -$4.17 N/A

Is PCVX or KOD more profitable?

Vaxcyte's return on equity of -32.51% beat Kodiak Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Vaxcyte N/A -32.51% -29.51% Kodiak Sciences N/A -253.85% -81.48%

Does the media favor PCVX or KOD?

In the previous week, Vaxcyte had 5 more articles in the media than Kodiak Sciences. MarketBeat recorded 9 mentions for Vaxcyte and 4 mentions for Kodiak Sciences. Kodiak Sciences' average media sentiment score of 0.97 beat Vaxcyte's score of 0.38 indicating that Kodiak Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vaxcyte 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kodiak Sciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, QGEN or KOD?

Qiagen has higher revenue and earnings than Kodiak Sciences. Kodiak Sciences is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Qiagen $2.09B 4.09 $424.88M $1.91 21.70 Kodiak Sciences N/A N/A -$229.97M -$4.17 N/A

Is QGEN or KOD more profitable?

Qiagen has a net margin of 19.16% compared to Kodiak Sciences' net margin of 0.00%. Qiagen's return on equity of 14.40% beat Kodiak Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Qiagen 19.16% 14.40% 8.40% Kodiak Sciences N/A -253.85% -81.48%

Does the media favor QGEN or KOD?

In the previous week, Qiagen had 10 more articles in the media than Kodiak Sciences. MarketBeat recorded 14 mentions for Qiagen and 4 mentions for Kodiak Sciences. Qiagen's average media sentiment score of 1.04 beat Kodiak Sciences' score of 0.97 indicating that Qiagen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Qiagen 9 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kodiak Sciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Kodiak Sciences (KOD) Competitors

$41.10 -0.21 (-0.51%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$41.13 +0.03 (+0.07%)

As of 07/13/2026 06:18 PM Eastern

Compare

KOD vs. KYMR, PRAX, PTGX, PCVX, and QGEN

Should you buy Kodiak Sciences stock or one of its competitors? MarketBeat compares Kodiak Sciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Kodiak Sciences include Kymera Therapeutics (KYMR), Praxis Precision Medicines (PRAX), Protagonist Therapeutics (PTGX), Vaxcyte (PCVX), and Qiagen (QGEN). These companies are all part of the "pharmaceutical products" industry.

How does Kodiak Sciences compare to Kymera Therapeutics?

Kymera Therapeutics (NASDAQ:KYMR) and Kodiak Sciences (NASDAQ:KOD) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

In the previous week, Kymera Therapeutics had 6 more articles in the media than Kodiak Sciences. MarketBeat recorded 10 mentions for Kymera Therapeutics and 4 mentions for Kodiak Sciences. Kodiak Sciences' average media sentiment score of 0.97 beat Kymera Therapeutics' score of 0.50 indicating that Kodiak Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kymera Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Kodiak Sciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

89.1% of Kodiak Sciences shares are held by institutional investors. 16.0% of Kymera Therapeutics shares are held by insiders. Comparatively, 44.4% of Kodiak Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Kymera Therapeutics currently has a consensus target price of $121.73, suggesting a potential upside of 10.26%. Kodiak Sciences has a consensus target price of $42.14, suggesting a potential upside of 2.54%. Given Kymera Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Kymera Therapeutics is more favorable than Kodiak Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	20 Buy rating(s)	1 Strong Buy rating(s)	2.91
Kodiak Sciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Kymera Therapeutics has a beta of 1.95, suggesting that its stock price is 95% more volatile than the broader market. Comparatively, Kodiak Sciences has a beta of 2.19, suggesting that its stock price is 119% more volatile than the broader market.

Kodiak Sciences has lower revenue, but higher earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Kodiak Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$39.21M	231.61	-$311.35M	-$3.57	N/A
Kodiak Sciences	N/A	N/A	-$229.97M	-$4.17	N/A

Kodiak Sciences has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -611.94%. Kymera Therapeutics' return on equity of -24.71% beat Kodiak Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-611.94%	-24.71%	-22.05%
Kodiak Sciences	N/A	-253.85%	-81.48%

Summary

Kymera Therapeutics beats Kodiak Sciences on 9 of the 16 factors compared between the two stocks.

How does Kodiak Sciences compare to Praxis Precision Medicines?

Kodiak Sciences (NASDAQ:KOD) and Praxis Precision Medicines (NASDAQ:PRAX) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, media sentiment, earnings, profitability and dividends.

Kodiak Sciences currently has a consensus price target of $42.14, suggesting a potential upside of 2.54%. Praxis Precision Medicines has a consensus price target of $563.50, suggesting a potential upside of 79.14%. Given Praxis Precision Medicines' stronger consensus rating and higher possible upside, analysts clearly believe Praxis Precision Medicines is more favorable than Kodiak Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kodiak Sciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Praxis Precision Medicines	2 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	4 Strong Buy rating(s)	2.95

In the previous week, Praxis Precision Medicines had 2 more articles in the media than Kodiak Sciences. MarketBeat recorded 6 mentions for Praxis Precision Medicines and 4 mentions for Kodiak Sciences. Kodiak Sciences' average media sentiment score of 0.97 beat Praxis Precision Medicines' score of 0.75 indicating that Kodiak Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kodiak Sciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Praxis Precision Medicines	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

89.1% of Kodiak Sciences shares are held by institutional investors. Comparatively, 67.8% of Praxis Precision Medicines shares are held by institutional investors. 44.4% of Kodiak Sciences shares are held by insiders. Comparatively, 3.0% of Praxis Precision Medicines shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Praxis Precision Medicines' return on equity of -43.02% beat Kodiak Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kodiak Sciences	N/A	-253.85%	-81.48%
Praxis Precision Medicines	N/A	-43.02%	-40.22%

Kodiak Sciences has higher earnings, but lower revenue than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Kodiak Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kodiak Sciences	N/A	N/A	-$229.97M	-$4.17	N/A
Praxis Precision Medicines	$8.55M	1,025.72	-$303.27M	-$13.37	N/A

Kodiak Sciences has a beta of 2.19, suggesting that its stock price is 119% more volatile than the broader market. Comparatively, Praxis Precision Medicines has a beta of 2.74, suggesting that its stock price is 174% more volatile than the broader market.

Summary

Praxis Precision Medicines beats Kodiak Sciences on 9 of the 15 factors compared between the two stocks.

How does Kodiak Sciences compare to Protagonist Therapeutics?

Kodiak Sciences (NASDAQ:KOD) and Protagonist Therapeutics (NASDAQ:PTGX) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, media sentiment, earnings and dividends.

Kodiak Sciences has a net margin of 0.00% compared to Protagonist Therapeutics' net margin of -154.88%. Protagonist Therapeutics' return on equity of -17.76% beat Kodiak Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kodiak Sciences	N/A	-253.85%	-81.48%
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%

Kodiak Sciences presently has a consensus target price of $42.14, suggesting a potential upside of 2.54%. Protagonist Therapeutics has a consensus target price of $116.93, suggesting a potential downside of 9.98%. Given Kodiak Sciences' higher probable upside, equities research analysts plainly believe Kodiak Sciences is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kodiak Sciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.94

89.1% of Kodiak Sciences shares are owned by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are owned by institutional investors. 44.4% of Kodiak Sciences shares are owned by company insiders. Comparatively, 5.2% of Protagonist Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Kodiak Sciences has a beta of 2.19, suggesting that its share price is 119% more volatile than the broader market. Comparatively, Protagonist Therapeutics has a beta of 1.79, suggesting that its share price is 79% more volatile than the broader market.

In the previous week, Protagonist Therapeutics had 6 more articles in the media than Kodiak Sciences. MarketBeat recorded 10 mentions for Protagonist Therapeutics and 4 mentions for Kodiak Sciences. Kodiak Sciences' average media sentiment score of 0.97 beat Protagonist Therapeutics' score of 0.67 indicating that Kodiak Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kodiak Sciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Protagonist Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Protagonist Therapeutics has higher revenue and earnings than Kodiak Sciences. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Kodiak Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kodiak Sciences	N/A	N/A	-$229.97M	-$4.17	N/A
Protagonist Therapeutics	$46.02M	181.51	-$130.15M	-$1.81	N/A

Summary

Protagonist Therapeutics beats Kodiak Sciences on 10 of the 16 factors compared between the two stocks.

How does Kodiak Sciences compare to Vaxcyte?

Vaxcyte (NASDAQ:PCVX) and Kodiak Sciences (NASDAQ:KOD) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk and earnings.

Vaxcyte has a beta of 1.22, meaning that its stock price is 22% more volatile than the broader market. Comparatively, Kodiak Sciences has a beta of 2.19, meaning that its stock price is 119% more volatile than the broader market.

Kodiak Sciences is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxcyte	N/A	N/A	-$766.63M	-$6.88	N/A
Kodiak Sciences	N/A	N/A	-$229.97M	-$4.17	N/A

In the previous week, Vaxcyte had 5 more articles in the media than Kodiak Sciences. MarketBeat recorded 9 mentions for Vaxcyte and 4 mentions for Kodiak Sciences. Kodiak Sciences' average media sentiment score of 0.97 beat Vaxcyte's score of 0.38 indicating that Kodiak Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vaxcyte	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kodiak Sciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vaxcyte currently has a consensus price target of $86.00, indicating a potential upside of 50.80%. Kodiak Sciences has a consensus price target of $42.14, indicating a potential upside of 2.54%. Given Vaxcyte's higher probable upside, research analysts plainly believe Vaxcyte is more favorable than Kodiak Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Kodiak Sciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

96.8% of Vaxcyte shares are held by institutional investors. Comparatively, 89.1% of Kodiak Sciences shares are held by institutional investors. 3.3% of Vaxcyte shares are held by company insiders. Comparatively, 44.4% of Kodiak Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Vaxcyte's return on equity of -32.51% beat Kodiak Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaxcyte	N/A	-32.51%	-29.51%
Kodiak Sciences	N/A	-253.85%	-81.48%

Summary

Vaxcyte beats Kodiak Sciences on 6 of the 11 factors compared between the two stocks.

How does Kodiak Sciences compare to Qiagen?

Qiagen (NYSE:QGEN) and Kodiak Sciences (NASDAQ:KOD) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, media sentiment, risk, analyst recommendations, earnings, institutional ownership, valuation and dividends.

Qiagen has a net margin of 19.16% compared to Kodiak Sciences' net margin of 0.00%. Qiagen's return on equity of 14.40% beat Kodiak Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qiagen	19.16%	14.40%	8.40%
Kodiak Sciences	N/A	-253.85%	-81.48%

Qiagen has higher revenue and earnings than Kodiak Sciences. Kodiak Sciences is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qiagen	$2.09B	4.09	$424.88M	$1.91	21.70
Kodiak Sciences	N/A	N/A	-$229.97M	-$4.17	N/A

Qiagen currently has a consensus target price of $43.15, suggesting a potential upside of 4.11%. Kodiak Sciences has a consensus target price of $42.14, suggesting a potential upside of 2.54%. Given Qiagen's higher possible upside, analysts clearly believe Qiagen is more favorable than Kodiak Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qiagen	1 Sell rating(s)	7 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.38
Kodiak Sciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

70.0% of Qiagen shares are held by institutional investors. Comparatively, 89.1% of Kodiak Sciences shares are held by institutional investors. 9.0% of Qiagen shares are held by company insiders. Comparatively, 44.4% of Kodiak Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Qiagen had 10 more articles in the media than Kodiak Sciences. MarketBeat recorded 14 mentions for Qiagen and 4 mentions for Kodiak Sciences. Qiagen's average media sentiment score of 1.04 beat Kodiak Sciences' score of 0.97 indicating that Qiagen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Qiagen	9 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kodiak Sciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Qiagen has a beta of 0.64, indicating that its stock price is 36% less volatile than the broader market. Comparatively, Kodiak Sciences has a beta of 2.19, indicating that its stock price is 119% more volatile than the broader market.

Summary

Qiagen beats Kodiak Sciences on 11 of the 16 factors compared between the two stocks.

Get Kodiak Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KOD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KOD vs. The Competition

Export

Metric	Kodiak Sciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.59B	$3.71B	$7.05B	$12.61B
Dividend Yield	N/A	2.20%	2.68%	8.00%
P/E Ratio	-9.86	20.85	27.11	24.26
Price / Sales	N/A	314.01	587.92	117.88
Price / Cash	N/A	61.98	29.22	49.36
Price / Book	13.84	8.49	10.75	6.29
Net Income	-$229.97M	$23.83M	$3.58B	$330.66M
7 Day Performance	7.31%	-3.56%	-2.06%	-1.32%
1 Month Performance	20.67%	6.31%	3.32%	-0.64%
1 Year Performance	694.97%	48.30%	26.35%	19.08%

Kodiak Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KOD Kodiak Sciences	0.5802 of 5 stars	$41.10 -0.5%	$42.14 +2.5%	+807.3%	$2.59B	N/A	N/A	90	Gap Down
KYMR Kymera Therapeutics	1.8857 of 5 stars	$114.76 +1.1%	$121.41 +5.8%	+148.2%	$9.34B	$39.21M	N/A	170	Analyst Downgrade Gap Down
PRAX Praxis Precision Medicines	3.0629 of 5 stars	$313.50 -1.6%	$569.63 +81.7%	+522.4%	$8.88B	$8.55M	N/A	110	Analyst Forecast
PTGX Protagonist Therapeutics	1.5561 of 5 stars	$131.50 -0.1%	$116.93 -11.1%	+145.1%	$8.46B	$46.02M	N/A	120
PCVX Vaxcyte	2.4739 of 5 stars	$56.96 -2.4%	$86.00 +51.0%	+58.7%	$8.43B	N/A	N/A	160

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KOD) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kodiak Sciences (KOD) Competitors

KOD vs. KYMR, PRAX, PTGX, PCVX, and QGEN

How does Kodiak Sciences compare to Kymera Therapeutics?

Summary

How does Kodiak Sciences compare to Praxis Precision Medicines?

Summary

How does Kodiak Sciences compare to Protagonist Therapeutics?

Summary

How does Kodiak Sciences compare to Vaxcyte?

Summary

How does Kodiak Sciences compare to Qiagen?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KOD vs. The Competition

Kodiak Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Kodiak Sciences (KOD) Competitors

KOD vs. KYMR, PRAX, PTGX, PCVX, and QGEN

How does Kodiak Sciences compare to Kymera Therapeutics?

Does the media prefer KYMR or KOD?

Do institutionals and insiders hold more shares of KYMR or KOD?

Do analysts rate KYMR or KOD?

Which has more volatility & risk, KYMR or KOD?

Which has stronger valuation and earnings, KYMR or KOD?

Is KYMR or KOD more profitable?

Summary

How does Kodiak Sciences compare to Praxis Precision Medicines?

Do analysts recommend KOD or PRAX?

Does the media prefer KOD or PRAX?

Do insiders and institutionals hold more shares of KOD or PRAX?

Is KOD or PRAX more profitable?

Which has preferable valuation and earnings, KOD or PRAX?

Which has more risk and volatility, KOD or PRAX?

Summary

How does Kodiak Sciences compare to Protagonist Therapeutics?

Is KOD or PTGX more profitable?

Do analysts recommend KOD or PTGX?

Do insiders and institutionals have more ownership in KOD or PTGX?

Which has more volatility & risk, KOD or PTGX?

Does the media favor KOD or PTGX?

Which has higher earnings & valuation, KOD or PTGX?

Summary

How does Kodiak Sciences compare to Vaxcyte?

Which has more volatility and risk, PCVX or KOD?

Which has stronger valuation and earnings, PCVX or KOD?

Does the media favor PCVX or KOD?

Do analysts recommend PCVX or KOD?

Do insiders & institutionals believe in PCVX or KOD?

Is PCVX or KOD more profitable?

Summary

How does Kodiak Sciences compare to Qiagen?

Is QGEN or KOD more profitable?

Which has better valuation and earnings, QGEN or KOD?

Do analysts rate QGEN or KOD?

Do institutionals & insiders hold more shares of QGEN or KOD?

Does the media favor QGEN or KOD?

Which has more risk & volatility, QGEN or KOD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KOD vs. The Competition

Kodiak Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools